rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.
![Rhythm Pharmaceuticals logo](/files/LOGO/1649904-RYTM.png)
Company profile
Ticker
RYTM
Exchange
Website
CEO
Hunter Smith
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
RHYTHM METABOLIC, INC.
SEC CIK
Corporate docs
Subsidiaries
Rhythm Pharmaceuticals Limited • Rhythm Securities Corp. • Rhythm Pharmaceuticals Netherlands, B.V. • Rhythm Pharmaceuticals UK Limited • Rhythm Pharmaceuticals France SAS • Rhythm Pharmaceuticals Italy S.r.L. • Rhythm Pharmaceuticals Canada Inc. • Rhythm Pharmaceuticals Germany GmbH • Xinvento, B.V. • Rhythm Pharmaceuticals Spain S.L. ...
RYTM stock data
Latest filings (excl ownership)
8-K
Other Events
10 Jul 24
424B7
Prospectus with selling stockholder info
10 Jul 24
DEFA14A
Additional proxy soliciting materials
17 Jun 24
8-K
Other Events
17 Jun 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
7 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Entry into a Material Definitive Agreement
16 Apr 24
Transcripts
RYTM
Earnings call transcript
2024 Q1
7 May 24
RYTM
Earnings call transcript
2023 Q4
22 Feb 24
RYTM
Earnings call transcript
2023 Q3
7 Nov 23
RYTM
Earnings call transcript
2023 Q2
1 Aug 23
RYTM
Earnings call transcript
2023 Q2
1 Aug 23
RYTM
Earnings call transcript
2023 Q1
2 May 23
RYTM
Earnings call transcript
2023 Q3
7 Mar 23
RYTM
Earnings call transcript
2022 Q4
1 Mar 23
RYTM
Earnings call transcript
2022 Q3
8 Nov 22
RYTM
Earnings call transcript
2022 Q2
2 Aug 22
Latest ownership filings
4
Joseph Shulman
18 Jul 24
144
Notice of proposed sale of securities
16 Jul 24
4
Joseph Shulman
16 Jul 24
144
Notice of proposed sale of securities
12 Jul 24
4
Alastair Garfield
10 Jul 24
3
Alastair Garfield
10 Jul 24
4
Stuart A Arbuckle
25 Jun 24
4
DAVID W J MCGIRR
25 Jun 24
4
LYNN A. TETRAULT
25 Jun 24
4
Edward T Mathers
25 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 53.89 mm | 53.89 mm | 53.89 mm | 53.89 mm | 53.89 mm | 53.89 mm |
Cash burn (monthly) | 2.17 mm | 4.68 mm | 47.02 mm | 22.76 mm | 13.58 mm | 11.71 mm |
Cash used (since last report) | 8.40 mm | 18.08 mm | 181.82 mm | 87.98 mm | 52.51 mm | 45.26 mm |
Cash remaining | 45.48 mm | 35.81 mm | -127.93 mm | -34.09 mm | 1.38 mm | 8.63 mm |
Runway (months of cash) | 20.9 | 7.7 | -2.7 | -1.5 | 0.1 | 0.7 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 164 |
Opened positions | 66 |
Closed positions | 25 |
Increased positions | 40 |
Reduced positions | 35 |
13F shares | Current |
---|---|
Total value | 2.53 tn |
Total shares | 66.04 mm |
Total puts | 84.10 k |
Total calls | 880.30 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 6.53 mm | $282.93 bn |
Baker Bros. Advisors | 6.40 mm | $277.24 bn |
Ra Capital Management | 5.33 mm | $230.97 bn |
GS Goldman Sachs | 5.11 mm | $221.49 bn |
Vanguard | 3.30 mm | $143.17 bn |
Perceptive Advisors | 3.27 mm | $141.63 bn |
STT State Street | 3.01 mm | $130.59 bn |
New Enterprise Associates 13 | 2.91 mm | $70.83 mm |
NEA Management | 2.91 mm | $126.09 bn |
Frazier Life Sciences Management | 2.19 mm | $94.90 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Jul 24 | Joseph Shulman | Common Stock | Sell | Dispose S | No | Yes | 53.0012 | 10,468 | 554.82 k | 30 |
16 Jul 24 | Joseph Shulman | Common Stock | Option exercise | Acquire M | No | No | 27.35 | 10,468 | 286.30 k | 10,498 |
16 Jul 24 | Joseph Shulman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 27.35 | 10,468 | 286.30 k | 23,032 |
12 Jul 24 | Joseph Shulman | Common Stock | Sell | Dispose S | No | Yes | 50.0141 | 5,313 | 265.72 k | 30 |
12 Jul 24 | Joseph Shulman | Common Stock | Option exercise | Acquire M | No | No | 21.38 | 5,313 | 113.59 k | 5,343 |
12 Jul 24 | Joseph Shulman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 21.38 | 5,313 | 113.59 k | 1,297 |
8 Jul 24 | Alastair Garfield | RSU Common Stock | Grant | Acquire A | No | No | 0 | 17,778 | 0.00 | 17,778 |
8 Jul 24 | Alastair Garfield | Stock Option Common Stock | Grant | Acquire A | No | No | 43.76 | 53,333 | 2.33 mm | 53,333 |
21 Jun 24 | Good Jennifer L | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,000 | 0.00 | 3,000 |
21 Jun 24 | Good Jennifer L | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,000 | 0.00 | 0 |
News
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts
25 Jul 24
Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $55
25 Jul 24
Rhythm Pharmaceuticals First Patients Dosed In Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 In Hypothalamic Obesity
23 Jul 24
Rhythm Pharmaceuticals Presents First Patient And Caregiver Reported Experiences From Phase 2 Trial Of Setmelanotide In Hypothalamic Obesity At ENDO 2024
3 Jun 24
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
8 May 24
Press releases
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
23 Jul 24
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
23 Jul 24
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11 Jul 24
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11 Jun 24
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
3 Jun 24